Vicore Pharma Holding AB (STU:6Y4) 3-Year Book Growth Rate : -2.50% (As of Dec. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Vicore Pharma Holding AB 3-Year Book Growth Rate?

Vicore Pharma Holding AB's Book Value per Share for the quarter that ended in Dec. 2024 was €0.42.

During the past 12 months, Vicore Pharma Holding AB's average Book Value per Share Growth Rate was 21.40% per year. During the past 3 years, the average Book Value per Share Growth Rate was -2.50% per year. During the past 5 years, the average Book Value per Share Growth Rate was -7.70% per year. During the past 10 years, the average Book Value per Share Growth Rate was 2.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

During the past 12 years, the highest 3-Year average Book Value per Share Growth Rate of Vicore Pharma Holding AB was 41.90% per year. The lowest was -18.00% per year. And the median was -2.50% per year.

Competitive Comparison of Vicore Pharma Holding AB's 3-Year Book Growth Rate

For the Biotechnology subindustry, Vicore Pharma Holding AB's 3-Year Book Growth Rate, along with its competitors' market caps and 3-Year Book Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Vicore Pharma Holding AB's 3-Year Book Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vicore Pharma Holding AB's 3-Year Book Growth Rate distribution charts can be found below:

* The bar in red indicates where Vicore Pharma Holding AB's 3-Year Book Growth Rate falls into.

Save Embed

;

Save Embed

;

Vicore Pharma Holding AB 3-Year Book Growth Rate Calculation

This is the 3-year average growth rate of Book Value per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

Vicore Pharma Holding AB (STU:6Y4) 3-Year Book Growth Rate Explanation

Book Value per Share is the ratio of equity available to common shareholders divided by the shares outstanding. Book value per share effectively indicates a firm's net asset value on a per-share basis. It can be used by investors to gauge whether a stock price is undervalued by comparing it to the firm's market value per share. Theoretically, it is what the shareholders will receive if the company is liquidated.

Vicore Pharma Holding AB 3-Year Book Growth Rate Related Terms

Thank you for viewing the detailed overview of Vicore Pharma Holding AB's 3-Year Book Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Vicore Pharma Holding AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vicore Pharma Holding AB (STU:6Y4) » Definitions » 3-Year Book Growth Rate

Comparable Companies

Traded in Other Exchanges

VICO:Sweden 6Y4:Germany

Address

Kornhamnstorg 53, Stockholm, SWE, 111 27

Website

https://www.vicorepharma.com

Vicore Pharma Holding AB is as a clinical-stage pharmaceutical company focused on severe lung diseases. The company is establishing a portfolio in respiratory diseases, including idiopathic pulmonary fibrosis (IPF). Its C21 is a small molecule angiotensin II type 2 receptor agonist (ATRAG) currently in phase 2a development for IPF. The company also has an investigational medical device in clinical development namely, Almee which is a digital therapeutic leveraging cognitive behavioral therapy created to address the psychological impact of living with pulmonary fibrosis.

Vicore Pharma Holding AB Headlines

No Headlines